Sezary SyndromeSymptoms, Doctors, Treatments, Advances & More
Learn About Sezary Syndrome
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Larisa Geskin is a Hematologist and a Dermatologist practicing medicine in New York, New York. Dr. Geskin is rated as an Elite provider by MediFind in the treatment of Sezary Syndrome. She is also highly rated in 18 other conditions, according to our data. Her clinical expertise encompasses Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Mycosis Fungoides, and Sezary Syndrome.
Christiane Querfeld, M.D., PH.D.
Christiane Querfeld is a Dermatologist practicing medicine in Duarte, California. Dr. Querfeld is rated as an Elite provider by MediFind in the treatment of Sezary Syndrome. She is also highly rated in 20 other conditions, according to our data. Her clinical expertise encompasses Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, and Sezary Syndrome.
Penn Dermatology Perelman
Alain Rook is a Dermatologist practicing medicine in Philadelphia, Pennsylvania. Dr. Rook is rated as an Elite provider by MediFind in the treatment of Sezary Syndrome. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, and Sezary Syndrome. Dr. Rook is board certified in Dermatology, 1991, Nephrology, 1980, and Internal Medicine, 1979. Dr. Rook is currently accepting new patients.
Summary: The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.
Summary: This is an open-label, single-arm, multicenter, phase II study combining pembrolizumab and mogamulizumab in patients with advanced-stage, relapsed or refractory CTCL Each cycle will equal 6 weeks. Pembrolizumab will be administered on Day 1 of each cycle. Mogamulizumab will be administered on Day 1, 8, 15, and 22 of Cycle 1. For Cycle 2 and subsequent cycles, mogamulizumab will be administered on ...